C
Clyde Bailey
Researcher at University of Arkansas for Medical Sciences
Publications - 34
Citations - 320
Clyde Bailey is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 9, co-authored 26 publications receiving 267 citations.
Papers
More filters
Journal ArticleDOI
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Elias Anaissie,Elizabeth Ann Coleman,Julia A. Goodwin,Robert L. Kennedy,Kimberly D. Lockhart,Carol Beth Stewart,Sharon K. Coon,Clyde Bailey,Bart Barlogie +8 more
TL;DR: The purpose of this retrospective study was to identify risk factors for VTE in NDMM and evaluate the effectiveness of LMWH.
Journal ArticleDOI
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
Rashid Z Khan,Madhav V. Dhodapkar,Adam Rosenthal,Christoph Heuck,Xenofon Papanikolaou,Pingping Qu,Frits van Rhee,Maurizio Zangari,Yogesh Jethava,Joshua Epstein,Shmuel Yaccoby,Antje Hoering,John Crowley,Nathan Petty,Clyde Bailey,Gareth J. Morgan,Bart Barlogie +16 more
TL;DR: High discriminatory power of a gene-based assay is demonstrated and a role for dysregulation of mitotic checkpoints in the context of genomic instability as a hallmark of high-risk smoldering myeloma is suggested.
Journal ArticleDOI
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
Saad Z. Usmani,Jeffrey R. Sawyer,Adam Rosenthal,Michele Cottler-Fox,Joshua Epstein,Shmuel Yaccoby,Rachael Sexton,Antje Hoering,Zeba N. Singh,Christoph Heuck,Sarah Waheed,Nabeel Chauhan,Donald J. Johann,Al-Ola Abdallah,Jameel Muzaffar,Nathan Petty,Clyde Bailey,John Crowley,Frits van Rhee,Bart Barlogie +19 more
TL;DR: Treatment, host, and myeloma features could be linked to MDS development after therapy for this malignancy, and periodic cytogenetic monitoring is recommended.
Journal ArticleDOI
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Yogesh Jethava,Alan Mitchell,Maurizio Zangari,Sarah Waheed,Carolina Schinke,Sharmilan Thanendrarajan,Jeffery R. Sawyer,Daisy Alapat,Erming Tian,Caleb K. Stein,Rashid Z Khan,Christoph Heuck,Nathan Petty,D Avery,Douglas Steward,R Smith,Clyde Bailey,Joshua Epstein,Shmuel Yaccoby,Antje Hoering,John Crowley,Gareth J. Morgan,Bart Barlogie,F. van Rhee +23 more
TL;DR: This regimen effectively reduced early mortality and relapse but failed to improve progression-free survival and overall survival due to relapse early during maintenance, according to the outcome of the Total Therapy 5 trial.
Journal ArticleDOI
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Jeffery R. Sawyer,Erming Tian,John D. Shaughnessy,Joshua Epstein,Charles M. Swanson,Colin Stangeby,C L Hale,L Parr,M Lynn,Gael Sammartino,Janet L. Lukacs,Caleb K. Stein,Clyde Bailey,Maurizio Zangari,Faith E. Davies,F. van Rhee,Bart Barlogie,Gareth J. Morgan +17 more
TL;DR: Findings indicate that current iFISH strategies may be uninformative or ambiguous in the detection of these clones, suggesting this patient subgroup maybe underreported, and identify a distinct numerical subgroup with cytogenetically defined high-risk disease.